• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $QURE

    uniQure N.V.

    Subscribe to $QURE
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: uniqure.com

    Peers

    $RGNX
    $VYGR

    Recent Analyst Ratings for uniQure N.V.

    DatePrice TargetRatingAnalyst
    4/1/2025$38.00Buy
    Chardan Capital Markets
    12/10/2024Outperform → Strong Buy
    Raymond James
    10/10/2024$20.00Outperform
    Raymond James
    2/29/2024$8.00Buy → Neutral
    Goldman
    12/19/2023$52.00 → $10.00Buy → Neutral
    Mizuho
    3/17/2022$40.00Neutral → Buy
    UBS
    12/17/2021$75.00 → $58.00Strong Buy → Outperform
    Raymond James
    10/27/2021$66.00Outperform
    William Blair
    7/27/2021$78.00 → $81.00Outperform
    Credit Suisse
    See more ratings

    uniQure N.V. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, Managing Director Kapusta Matthew C was granted 99,000 units of Ordinary Shares and sold $291,629 worth of Ordinary Shares (28,341 units at $10.29), increasing direct ownership by 12% to 651,454 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      3/5/25 5:32:51 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Abi-Saab Walid was granted 38,000 units of Ordinary Shares and sold $13,891 worth of Ordinary Shares (1,350 units at $10.29), increasing direct ownership by 32% to 151,903 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      3/5/25 5:28:57 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Klemt Christian was granted 73,000 units of Ordinary Shares and sold $107,407 worth of Ordinary Shares (10,438 units at $10.29), increasing direct ownership by 40% to 217,730 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      3/5/25 5:25:33 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Potts Jeannette was granted 35,000 units of Ordinary Shares and sold $72,812 worth of Ordinary Shares (7,076 units at $10.29), increasing direct ownership by 30% to 119,743 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      3/5/25 5:21:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO, Managing Director Kapusta Matthew C sold $362,015 worth of Ordinary Shares (33,444 units at $10.82) and was granted 16,324 units of Ordinary Shares, decreasing direct ownership by 3% to 580,795 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      2/27/25 7:33:13 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Klemt Christian sold $186,458 worth of Ordinary Shares (17,257 units at $10.80) and was granted 5,712 units of Ordinary Shares, decreasing direct ownership by 7% to 155,168 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      2/27/25 7:29:31 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO, Managing Director Kapusta Matthew C exercised 100,000 units of Ordinary Shares at a strike of $14.71 and sold $1,503,000 worth of Ordinary Shares (100,000 units at $15.03) (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      12/12/24 4:54:07 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO, Managing Director Kapusta Matthew C was granted 10,494 units of Ordinary Shares and sold $26,079 worth of Ordinary Shares (3,418 units at $7.63), increasing direct ownership by 1% to 597,915 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      12/10/24 5:03:40 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Klemt Christian was granted 3,672 units of Ordinary Shares and sold $13,560 worth of Ordinary Shares (1,796 units at $7.55), increasing direct ownership by 1% to 166,713 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      12/10/24 4:54:22 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Abi-Saab Walid sold $6,309 worth of Ordinary Shares (1,447 units at $4.36), decreasing direct ownership by 1% to 115,253 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      6/28/24 4:21:42 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    uniQure N.V. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

      ~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 ~ ~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of March 31, 2025 expected to fund operations into second half o

      5/9/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure to Announce First Quarter 2025 Financial Results

      LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is initiating quarterly earnings calls to provide regular updates on progress and to enhance engagement with the investment community. The event will be webcast under the Events & Presentations section of uniQure's

      5/5/25 4:05:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

      ~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics License Application submission expected in the second quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, April 17, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington's disease, a rare, inherited neurodegenerative disorder for which the

      4/17/25 7:17:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

      ~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~ ~ Completed patient enrollment in the third cohort of the Phase I/II study of AMT-130 ~ ~ Initiated dosing of the Phase I/II study of AMT-260 in mesial temporal lobe epilepsy (mTLE); Implementing protocol changes to expand study inclusion criteria ~ ~ Completed enrollment of the first cohorts in the Phase I/II studies of AMT-191 in Fabry disease and AMT-162 in SOD1-ALS; Received favorable recommendations

      2/27/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

      94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatmentMean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX in the treatment of hemophilia BPhase 3 HOPE-B data showed that a one-time treatment with HEMGENIX provided long-term bleed protection as mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by approximately 90% from lead-in as compared to year fourKING OF PRUSSIA, Pa., Feb. 7, 2025 /PRNewswire/ -- Global biotechnology leader CSL ((ASX:CSL, OTC:CSLLY) today announced the four-year results from the

      2/7/25 9:12:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

      ~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~ ~ Company expects to initiate enrollment of second dose cohort in the first quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of enrollment in the first cohort of the Phase I/IIa trial of AMT-191, an investigational gene therapy for the treatment of Fabry disease. Additionally, the Independent Data Monitoring Committee (IDMC) reviewed safety data from the initia

      2/3/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

      ~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ ~ Company Expects to Initiate Enrollment of Second Dose Cohort in the First Quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM, Jan. 30, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Independent Data Monitoring Committee (IDMC) for EPISOD1, uniQure's Phase I/II clinical trial of AMT-162, an investigational gene therapy for amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene

      1/30/25 7:37:32 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Pricing of its Public Offering

      LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4,411,764 of its ordinary shares at a public offering price of $17.00 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $75 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to pu

      1/8/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Proposed Public Offering

      LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to 15% additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assuran

      1/7/25 4:49:48 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

      ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~         ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company reached agreement

      12/10/24 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    uniQure N.V. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/14/24 12:01:42 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/13/24 4:05:14 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      10/25/24 9:48:27 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      10/18/24 12:07:05 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by uniQure N.V.

      SC 13G - uniQure N.V. (0001590560) (Subject)

      7/18/24 4:52:39 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by uniQure N.V. (Amendment)

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      2/14/24 4:51:41 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by uniQure N.V.

      SC 13G - uniQure N.V. (0001590560) (Subject)

      2/13/24 4:33:59 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by uniQure N.V. (Amendment)

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      2/9/24 10:05:20 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by uniQure N.V. (Amendment)

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      1/25/24 9:31:29 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by uniQure N.V. (Amendment)

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      10/6/23 2:34:36 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    uniQure N.V. SEC Filings

    See more
    • SEC Form 10-Q filed by uniQure N.V.

      10-Q - uniQure N.V. (0001590560) (Filer)

      5/9/25 7:40:19 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      5/9/25 7:13:06 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by uniQure N.V.

      DEFA14A - uniQure N.V. (0001590560) (Filer)

      4/28/25 6:03:12 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by uniQure N.V.

      DEF 14A - uniQure N.V. (0001590560) (Filer)

      4/28/25 6:01:42 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by uniQure N.V.

      PRE 14A - uniQure N.V. (0001590560) (Filer)

      4/16/25 6:02:31 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure N.V. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      4/16/25 6:00:17 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by uniQure N.V.

      10-K - uniQure N.V. (0001590560) (Filer)

      2/27/25 8:45:34 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      2/27/25 8:03:38 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      1/8/25 4:25:20 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by uniQure N.V.

      424B5 - uniQure N.V. (0001590560) (Filer)

      1/8/25 4:21:56 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    uniQure N.V. Leadership Updates

    Live Leadership Updates

    See more
    • uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

      LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

      6/26/23 7:11:42 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership Team

      Sander van Deventer is co-founder and former Chief Technology Officer of the Company Elena Ritsou assumes role of Chief Corporate Officer Barbara Sanders is promoted to Chief Technology Officer Industry veteran Frank Walsh joins as an Independent Board Member VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative diseases, today announces the appointment of Sander van Deventer, co-founder and formerly Chief Technology Officer, as Chief Executive Officer. The Company has also made key appointments to its leadership team. Sander van Deventer has 25 years of experience in drug development and a longstanding

      11/8/22 4:00:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

      Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a next generation gene therapy company developing first-in-class transformative therapies with advanced lentiviral vectors, today announces the appointment of Dr. Sabah Sallah MD, PhD as Chief Medical Officer. Dr. Sallah will lead the Company's clinical strategy, development and operations as Genespire progresses its novel advanced lentiviral gene therapy platforms towards the clinic. Dr. Sallah is a board-certified hematologist who has spent more than

      7/7/22 2:00:00 AM ET
      $FRLN
      $QURE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

      NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems are implicated, today announced the appointment of Rachelle Jacques as President and Chief Executive Officer of Akari Therapeutics. Ms. Jacques will also join the company's Board of Directors. Her appointment begins at the end of March 2022. Outgoing Chief Executive Officer, Clive Richardson, will continue to serve the Company, supporting Rachelle to accelerate business development and ensuring a smooth transition."

      3/2/22 7:00:00 AM ET
      $AKTX
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

      ~ Completed 78-week follow-up for hemophilia B pivotal study, with top-line data expected by year-end 2021 ~ ~ Enrolled 14 patients to date in Phase 1/2 clinical trial of AMT-130 in Huntington's Disease, with no significant safety concerns observed ~ ~ Preliminary data on first four patients in ongoing Phase I/II clinical trial of AMT-130 and initiation of European Phase Ib/II clinical trial expected by year-end 2021 ~ ~ Closed acquisition of Corlieve Therapeutics adding preclinical program in temporal lobe epilepsy to proprietary research pipeline ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 25, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy com

      10/25/21 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

      LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the Board's Audit Committee, has more than 25 years of industry experience in strategic, cross-functional executive roles spanning finance, business operations, manufacturing, and commercial. She has led successful launches of several rare disease therapies including the recent approval of a Regenerative Medicine Advanced Therapy (RMAT)-designated product, one of only three since the p

      10/21/21 9:30:00 AM ET
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    uniQure N.V. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets resumed coverage on uniQure with a new price target

      Chardan Capital Markets resumed coverage of uniQure with a rating of Buy and set a new price target of $38.00

      4/1/25 8:05:22 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure upgraded by Raymond James

      Raymond James upgraded uniQure from Outperform to Strong Buy

      12/10/24 11:36:55 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on uniQure with a new price target

      Raymond James resumed coverage of uniQure with a rating of Outperform and set a new price target of $20.00

      10/10/24 8:37:20 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure downgraded by Goldman with a new price target

      Goldman downgraded uniQure from Buy to Neutral and set a new price target of $8.00

      2/29/24 8:52:31 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure downgraded by Mizuho with a new price target

      Mizuho downgraded uniQure from Buy to Neutral and set a new price target of $10.00 from $52.00 previously

      12/19/23 7:34:17 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure upgraded by UBS with a new price target

      UBS upgraded uniQure from Neutral to Buy and set a new price target of $40.00

      3/17/22 7:10:33 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure downgraded by Raymond James with a new price target

      Raymond James downgraded uniQure from Strong Buy to Outperform and set a new price target of $58.00 from $75.00 previously

      12/17/21 4:33:32 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on uniQure with a new price target

      William Blair initiated coverage of uniQure with a rating of Outperform and set a new price target of $66.00

      10/27/21 8:41:08 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse reiterated coverage on uniQure with a new price target

      Credit Suisse reiterated coverage of uniQure with a rating of Outperform and set a new price target of $81.00 from $78.00 previously

      7/27/21 9:03:10 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on uniQure with a new price target

      BTIG Research initiated coverage of uniQure with a rating of Buy and set a new price target of $46.00

      6/15/21 7:10:01 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    uniQure N.V. Financials

    Live finance-specific insights

    See more
    • uniQure to Announce First Quarter 2025 Financial Results

      LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is initiating quarterly earnings calls to provide regular updates on progress and to enhance engagement with the investment community. The event will be webcast under the Events & Presentations section of uniQure's

      5/5/25 4:05:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

      ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~         ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company reached agreement

      12/10/24 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

      ~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted external control ~ ~ Achieved statistically significant lowering of CSF neurofilament light protein (NfL) compared to baseline at 24 months in patients treated with AMT-130; Mean CSF NfL levels for both doses were below baseline at 24 months ~ ~ Granted first-ever Regenerative Medicine Advanced Therapy (RMAT) designation in Huntington's disease; uniQure expects to meet with the FDA in t

      7/9/24 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

      ~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean CSF NfL continue to demonstrate favorable trends with low-dose patients below baseline at 30 months and high-dose patients near baseline at 18 months ~ ~ AMT-130 continues to be generally well-tolerated across both doses ~ ~ Data support continuing clinical development of AMT-130 and pursuing regulatory interactions to discuss potential strategies for ongoing development ~ ~ Investor conference call and webcast today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, D

      12/19/23 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

      ~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history of the disease ~ ~ Neurofilament Light Chain (NfL) in cerebrospinal fluid (CSF) was below baseline at 24 months in patients treated with the low-dose of AMT-130 and declining towards baseline at 12 months in patients treated with the high-dose of AMT-130 ~ ~ Suppression of CSF mHTT in low-dose cohort supports AMT-130 target engagement; Greater variability observed in high-dose cohort ~ ~ Promising data support continuing clinical development of AMT-130 and pursuing regulatory interacti

      6/21/23 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1

       ~ License of APB-102 further strengthens uniQure's pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure's c9orf72-ALS program have the potential to address most inherited forms of ALS ~~ uniQure plans to initiate a Phase I/II trial of APB-102 in the second half of 2023 ~ LEXINGTON, Mass. and AMSTERDAM and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, and Apic Bio, an innovative gene therapy company developing novel treatment options for patients with rare genetic diseas

      1/31/23 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

      ~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington's disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant Huntingtin protein (mHTT) observed in cerebral spinal fluid (CSF) ~ ~ Announced postponement of AMT-130 higher-dose procedures due to recent suspected unexpected severe adverse reactions at this dose; Lower-dose procedures are not affected and no impact is expected on anticipated data readouts in 2023 ~ ~ Advancing regulatory reviews of the U.S. and European marketing applications for etranacogene dezaparvovec in hemophilia B ~ ~ Investor conference call and webcast today at 8:30 a.m.

      8/8/22 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

      ~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with AMT-130 ~ ~ Neurofilament Light Chain (NfL) in CSF near baseline at 12 months in patients treated with AMT-130 ~ ~ Biomarker and clinical data including 24-month follow-up in the low-dose U.S. cohort and 12-month follow up in the high-dose U.S. cohort expected in first half of 2023 ~ ~ Investor conference call and webcast today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 23, 2022 (GLOBE NEWSWIRE) --

      6/23/22 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

      ~ Treatment was well tolerated with no significant safety issues related to AMT-130 in first two treated patients through one year of follow-up ~ ~ Neurofilament Light Chain (NfL) rose as expected immediately following surgery and returned to baseline in treated patients ~ ~ A total of 19 patient procedures have been performed in the U.S. Phase I/II clinical trial, with higher-dose cohort enrollment expected to be completed by mid-2022 ~ ~ Screening initiated in European open-label Phase I/II study ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Dec. 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company ad

      12/16/21 7:00:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting

      ~ Strong Presence at ASH Featuring Five Presentations, Including Late-BreakingOral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday, December 8, 2020 at 5:00 p.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, will present clinical data from the HOPE-B pivotal trial of etranacogene dezaparvovec in hemophilia B

      11/30/20 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care